caffeine 100 MG / ergotamine tartrate 2 MG Rectal Suppository [Migergot]

What the CMS Formulary Data Shows for caffeine 100 MG / ergotamine tartrate 2 MG Rectal Suppository [Migergot]

Per the CMS 2026 Part D formulary file, caffeine 100 MG / ergotamine tartrate 2 MG Rectal Suppository [Migergot] (RxNorm concept RXCUI 1293639, generic name caffeine) appears on 20 distinct formulary files spanning 403 Medicare Part D plan offerings - 8% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 6, with a cross-plan average of Tier 4.3.

Real-world access to caffeine 100 MG / ergotamine tartrate 2 MG Rectal Suppository [Migergot] depends on utilization management as much as tier placement: 0% of covering formularies require prior authorization. 0% require step therapy. 35% apply quantity limits.

Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 96 Part D beneficiaries filled caffeine 100 MG / ergotamine tartrate 2 MG Rectal Suppository [Migergot] in 2023, with total plan-and-beneficiary spending of $2,376,123 and an average per-beneficiary annual cost of $24,751.28. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry caffeine 100 MG / ergotamine tartrate 2 MG Rectal Suppository [Migergot] today.